DBV Technologies S.A.
About DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $5.6M
- Net income
- -$146.9M
- Total assets
- $233.7M
- Market cap
- $981.9M
- Operating margin
- -2609.2%
- Net margin
- -2607.3%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $5.6M
- Operating expenses
- $152.7M
- Operating income
- -$147.1M
- Income tax
- $491.0K
- Net income
- -$146.9M
- EPS (basic)
- $-1.05
- EPS (diluted)
- $-1.05
Balance sheet
- Total assets
- $233.7M
- Current assets
- $212.9M
- Total liabilities
- $64.9M
- Current liabilities
- $58.0M
- Shareholders’ equity
- $168.8M
Cash flow
- Operating cash flow
- -$121.2M
- Investing cash flow
- -$1.4M
- Financing cash flow
- $276.2M
- Net cash flow
- $153.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $981.9M
- EPS (diluted)
- $-1.05
- Shares outstanding
- 61.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 22, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $146.9M in FY2025.
- Revenue declined 1% from FY2021 to FY2025.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review DBV Technologies S.A..
Write a review
News about DBV Technologies S.A.
News & sentiment via Polygon.io
